Evidence map›Paper›PMID 27269866›Full record

ArticleACS chemical neuroscience2016

6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

Dwight A Williams, Yi Zheng, Bethany G David, Yunyun Yuan, Saheem A Zaidi, David L Stevens, Krista L Scoggins, Dana E Selley, William L Dewey, Hamid I Akbarali and 1 more

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Strategies for DevelopingThe Journal of pharmacology and experimental therapeutics · 2020
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Dwight A WilliamsDepartment of Medicinal Chemistry, Virginia Commonwealth University , 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Yi ZhengDepartment of Medicinal Chemistry, Virginia Commonwealth University , 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Bethany G DavidDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
Yunyun YuanDepartment of Medicinal Chemistry, Virginia Commonwealth University , 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Saheem A ZaidiDepartment of Medicinal Chemistry, Virginia Commonwealth University , 800 E. Leigh Street, Richmond, Virginia 23298, United States.
David L StevensDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
Krista L ScogginsDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
Dana E SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
William L DeweyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
Hamid I AkbaraliDepartment of Pharmacology and Toxicology, Virginia Commonwealth University , 410 North 12th Street, Richmond, Virginia 23298, United States.
Yan ZhangDepartment of Medicinal Chemistry, Virginia Commonwealth University , 800 E. Leigh Street, Richmond, Virginia 23298, United States.
Virginia Commonwealth University · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI YAN ZHANG · 2014 to 2026
$13.8M
Non-peptide Mu Opioid Receptor Selective AntagonistsR01DA024022 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2009 to 2019
$3.5M
Opioid tolerance and bowel dysfunctionR01DA024009 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI AKBARALI, HAMID I, DEWEY, WILLIAM L. · 2009 to 2015
$2.1M
NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA024009NIDA NIH HHS R01 DA024022NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

The 6β-N-heterocyclic naltrexamine derivative, NAP, has been demonstrated to be a peripherally selective mu opioid receptor modulator. To further improve peripheral selectivity of this highly potent ligand, its pyridal ring was quaterinized with benzyl bromide to produce BNAP. In radioligand binding assay, the Ki of BNAP for MOR was 0.76 ± 0.09 nM and was >900-fold more selective for MOR than DOR. The Ki for KOR was 3.46 ± 0.05 nM. In [(35)S]GTPγS ligand stimulated assay, BNAP showed low agonist efficacy with 14.6% of the maximum response of DAMGO with an EC50 of 4.84 ± 0.6 nM. However, unlike its parent compound NAP, BNAP displayed partial agonist activity at KOR with % maximum response at 45.9 ± 1.7% of U50,488H. BNAP did not reverse morphine-induced antinociception when administered subcutaneously but did antagonize when administered intracerebroventricularly. BNAP antagonized morphine-induced contractions of the circular muscle in mice colon. BNAP inhibition of field-stimulated contractions in longitudinal muscle strips for the guinea-pig ileum were also blocked by nor-BNI, a kappa opioid receptor antagonist. BNAP induced inhibition of acetic acid induced abdominal stretching in chronic morphine treated mice. These findings suggest that BNAP is a dual MOR antagonist/KOR agonist and may have functional use in irritable bowel patients.

Indexed as

AnimalsBinding, CompetitiveCHO CellsCricetulusDisease Models, AnimalGastrointestinal MotilityGuanosine 5'-O-(3-Thiotriphosphate)Guinea PigsIleumIn Vitro TechniquesLigandsMaleMiceMuscle ContractionMuscle, SkeletalMuscle, SmoothBNAP compoundGuanosine 5'-O-(3-Thiotriphosphate)LigandsNaltrexoneReceptors, Opioid, kappaReceptors, Opioid, muirritable bowel syndromemixed opioid ligandopioid induced constipationPeriphery selectivityvisceral pain

Identifiers

PMID27269866
PMCPMC5125022
OpenAlexW2409770495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.